mapo/iStock via Getty Images Rapport Therapeutics ( RAPP ), backed by the venture capital arm of Johnson & Johnson ( JNJ ), on Thursday announced the pricing of its initial public offering of 8M shares of its common stock at a public offering price of $17.00 per share. The gross proceeds to Rapport ( RAPP ) from the initial public offering and the concurrent private placement, are expected to be approximately $154 million.
Rapport’s ( RAPP ) shares are expected to begin trading on the Nasdaq Global Market on June 7, under the ticker symbol “RAPP.” The offering is expected to close on June 10. Source: Press Release More on Rapport Therapeutics, Inc.
Rapport Therapeutics Seeks IPO For CNS Treatment Programs J&J-backed Rapport Therapeutics sets terms for $136M IPO J&J-backed Rapport Therapeutics files for $100M IPO Financial information for Rapport Therapeutics, Inc..
